Norwegian version of this page

Tumour Marker Group

Immunoassay techniques have revolutionized the determination of clinically relevant proteins and peptides. We are one of the few hospital laboratories that still develops, validates and introduces novel “in house” assays into the clinic.

About the group

We have more than 25 years of experience in the production of monoclonal antibodies (mAbs) for use in the construction of these specialized assays.

Many of our mAbs have been licensed and are used in the manufacture of commercial assay kits that are in worldwide use.


We have thoroughly studied the challenges related to immunometric assays, particularly the problems caused by heterophilic antibodies or human anti-mouse antibodies. 

We have also undertaken extensive studies on the incidence and prevention of interference in immunometric assays.


We have established assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases such as rheumatoid arthritis and Crohn’s disease.

Recently, we have also developed assays for PD-1 and CTLA-4 inhibitors, the new blockbuster drugs used in immunotherapy in oncology.

By monitoring serum concentrations of these effective and expensive drugs, and identifying patients who produce neutralizing antibodies, clinicians may optimize the treatment for each individual patient.


  • Validating immunoassays for human epidermal growth factor receptors 2, 3 and 4 as tumour markers for HER2 positive breast cancer
  • Investigating the potential effect of combinatorial treatment of melanoma with PLX4032 (vemurafenib) and HER antibodies (in vitro studies)
  • Development and validation of immunoassays for novel immunotherapy drugs such as KEYTRUDA (pembrolizumab), OPDIVO (nivolumab) and YERVOY (ipilimumab)
  • Monitoring serum concentrations of immunotherapy drugs in patients with lung cancer and malignant melanoma.
    Collaboration with the clinicians at the hospital
  • Developing assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases.
    Collaboration study with the Department of Pharmacology and clinicians at Rikshospitalet and Diakonhjemmet
  • Developing assays for measuring monoclonal antibodies used in treatment of cancer
  • Late effects after testicular cancer; thyroid and kidney function.
    Collaboration with National Advisory Unit on Late Effects after Cancer Treatment
  • Two dimensional chromatography combined with mass spectrometry is used to identify and quantitative tumour markers.
    Collaboration with Department of Pharmaceutical Chemistry, UiO
  • Validating different markers for potential development of assays clinically useful in daily practice.
    Part of the collaboration study “Hallmarks in lung cancer"
Published Sep. 5, 2017 3:07 PM - Last modified Sep. 5, 2017 3:07 PM


Group leader


  • Trine Bjøro
  • David Warren
  • Sigurd Bøe
  • Johanna Géhin
  • Miriam Øijordsbakken
  • Karoline Johansen Henanger
  • Kjell Nustad
  • Nils Bolstad
  • Ragnhild Nome
  • Kari Hauge Olsen
  • Elisabeth Paus
Detailed list of participants